Skip to main content
. 2016 Aug 3;25(14):1587–1596. doi: 10.1177/0961203316655215

Figure 2.

Figure 2

Patient disposition.

aPatients excluded as they did not receive steroids, AM or IS.

AE: adverse event; AM: antimalarial; BLISS: A Study of Belimumab in Subjects with Systemic Lupus Erythematosus; F/U: follow-up; IS: immunosuppressant; ITT: intent-to-treat.